3,159
Participants
Start Date
February 24, 2021
Primary Completion Date
June 29, 2023
Study Completion Date
June 29, 2023
SARS-CoV-2 recombinant protein vaccine Phase 2 Formulation 1
Pharmaceutical form: Emulsion for injection Route of administration: Intramuscular injection
SARS-CoV-2 recombinant protein vaccine Phase 2 Formulation 2
Pharmaceutical form: Emulsion for injection Route of administration: Intramuscular injection
SARS-CoV-2 recombinant protein vaccine Phase 2 Formulation 3
Pharmaceutical form: Emulsion for injection Route of administration: Intramuscular injection
SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (D614)-AS03, Dosage A
Pharmaceutical form: Emulsion for injection Route of administration: Intramuscular injection
SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (B.1.351)-AS03
Pharmaceutical form: Emulsion for injection Route of administration: Intramuscular injection
SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (D614)-AS03, Dosage B
Pharmaceutical form: Emulsion for injection Route of administration: Intramuscular injection
SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (B.1.351)-AS03 Alternative Exploratory Formulation 1
Pharmaceutical form: Emulsion for injection Route of administration: Intramuscular injection
SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (B.1.351)-AS03 Alternative Exploratory Formulation 2
Pharmaceutical form: Emulsion for injection Route of administration: Intramuscular injection
SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (B.1.351)-AS03 Alternative Exploratory Formulation 3
Pharmaceutical form: Emulsion for injection Route of administration: Intramuscular injection
SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (B.1.351)-AS03 Alternative Exploratory Formulation 4
Pharmaceutical form: Emulsion for injection Route of administration: Intramuscular injection
SARS-CoV-2 adjuvanted recombinant protein vaccine, bivalent (D614+B.1.351)-AS03
Pharmaceutical form: Emulsion for injection Route of administration: Intramuscular injection
Investigational Site Number : 0360005, Westmead
Investigational Site Number : 5540001, Rotorua
Investigational Site Number : 5540007, Nawton
Investigational Site Number : 0360001, South Brisbane
Investigational Site Number : 0360002, Southport
Investigational Site Number : 0360004, Woodville
Investigational Site Number : 0360003, Norwood
Investigational Site Number : 5540010, Nelson
Investigational Site Number : 5540002, Christchurch
New York University Langone Vaccine Center Site Number : 8400230, New York
Columbia University Irving Medical Center Site Number : 8400203, New York
Investigational Site Number : 3400002, Municipio Del Distrito Central
NYU VC-Augustana Site Number : 8400267, Brooklyn
Investigational Site Number : 2500015, Marseille
Investigational Site Number : 2500016, Marseille
University of Rochester Site Number : 8400207, Rochester
University of Pittsburgh Site Number : 8400233, Pittsburgh
Investigational Site Number : 7240013, Santiago de Compostela
The George Washington University Site Number : 8400212, Washington D.C.
Optimal Research, LLC Rockville Site Number : 8400048, Rockville
Investigational Site Number : 2500013, Dijon
Investigational Site Number : 3400001, San Pedro Sula
Investigational Site Number : 7240009, Madrid
Investigational Site Number : 7240016, Majadahonda
Coastal Carolina Research Center Site Number : 8400097, North Charleston
Emory University Decatur Site Number : 8400201, Decatur
Synexus Clinical Research US, Inc. - Orlando Site Number : 8400179, Orlando
Optimal Research, LLC Site Number : 8400057, Melbourne
Cenexel Research Centers of America Site Number : 8400089, Hollywood
Investigational Site Number : 2500003, Pessac
Investigational Site Number : 2500004, Rennes
Synexus - Clinical Research Advantage, Inc. Site Number : 8400270, Birmingham
Investigational Site Number : 7240003, Vigo
Investigational Site Number : 2500002, Tours
Investigational Site Number : 2500006, Nantes
Investigational Site Number : 7240008, Valencia
Synexus Clinical Research Evansville Site Number : 8400272, Evansville
American Indian Clinical Trials Research Network Site Number : 8400204, Rapid City
Chicago Clinical Research Institute, Inc. Site Number : 8400269, Chicago
Optimal Research Site Number : 8400187, Peoria
Synexus St. Louis Site Number : 8400100, St Louis
Velocity Clinical Research, Omaha Site Number : 8400030, Omaha
Investigational Site Number : 2500014, Lyon
Investigational Site Number : 2500007, Pierre-Bénite
Research Works INC Site Number : 8400045, New Orleans
Baptist Health Center for Clinical Research Site Number : 8400077, Little Rock
Investigational Site Number : 2500005, Paris
AES Austin Site Number : 8400191, Austin
Synexus Chandler Site Number : 8400251, Chandler
Synexus - Glendale. Site Number : 8400271, Glendale
Investigational Site Number : 2500008, Limoges
Charles R. Drew University of Medicine and Science Site Number : 8400220, Los Angeles
Peninsula Research Associates, Inc. Site Number : 8400094, Rolling Hills Estates
Optimal Research Site Number : 8400173, San Diego
Yale University Site Number : 8400239, New Haven
Brigham and Women's Hospital Site Number : 8400199, Boston
Holy Name Medical Center Site Number : 8400072, Teaneck
Investigational Site Number : 5540005, New Lynn
Investigational Site Number : 8260011, Runcorn
Investigational Site Number : 8260017, Bath
Investigational Site Number : 8260013, Surrey
Investigational Site Number : 8260014, Doncaster
Investigational Site Number : 8260016, Gloucester
Investigational Site Number : 8260010, Harrow
Investigational Site Number : 8260015, London
Investigational Site Number : 8260012, Southampton
Collaborators (1)
GlaxoSmithKline
INDUSTRY
Sanofi Pasteur, a Sanofi Company
INDUSTRY